WO2012134165A2 - Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait de semence de psoraleae - Google Patents

Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait de semence de psoraleae Download PDF

Info

Publication number
WO2012134165A2
WO2012134165A2 PCT/KR2012/002273 KR2012002273W WO2012134165A2 WO 2012134165 A2 WO2012134165 A2 WO 2012134165A2 KR 2012002273 W KR2012002273 W KR 2012002273W WO 2012134165 A2 WO2012134165 A2 WO 2012134165A2
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
composition
extract
present
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/002273
Other languages
English (en)
Korean (ko)
Other versions
WO2012134165A3 (fr
Inventor
황성연
정경채
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Bio Medical Science Institute Co Ltd
Original Assignee
Korea Bio Medical Science Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Bio Medical Science Institute Co Ltd filed Critical Korea Bio Medical Science Institute Co Ltd
Publication of WO2012134165A2 publication Critical patent/WO2012134165A2/fr
Publication of WO2012134165A3 publication Critical patent/WO2012134165A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/487—Psoralea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Definitions

  • the present invention relates to a novel use of Bogolgo extract.
  • the present invention relates to therapeutic compositions and cosmetic compositions containing Bogolji extract as an active ingredient exhibiting excellent prophylactic or therapeutic efficacy against lung cancer.
  • lung cancer is a malignant tumor in the lung, and it can be divided into primary lung cancer, which is the first cancer cell in bronchial tissue, bronchiole, alveoli, etc. have.
  • Non-small cell lung cancer which accounts for 80% to 85% of the total lung cancer, can be treated by surgical treatment when diagnosed early. Due to the nature of difficult lung cancer, it is often found late and difficult to treat.
  • Non-small cell lung cancer consists of three subtypes: 40% adenocarcinoma, 40% squamous cell carcinoma and 20% large cell carcinoma.
  • TMN staging system is widely accepted for the management of lung cancer.
  • T1-T4 Primary tumors are divided into four T categories (T1-T4) according to tumor size, site and local involvement. Lymph node spread is delivered into the bronchus / pulmonary in the lung (N1), medial spread on the same side as the primary tumor (N2) and mediastinal spread across the primary lung tumor. Or supraclavilcular involvement (N3). There is no distant or metastatic spread (M0 or M1). In general, lung cancer that has not metastasized is treated by surgical removal. However, recurrence rates after lung cancer removal surgery are high, ranging from 20 to 50% (Cancer: Principles & Practice of Oncology, 56th. Ed. In: Devita DV, Hellman S, Rosenberg SA, eds. ).
  • non-small cell lung cancer has a high recurrence rate after treatment, and compared with a high incidence rate, resistance to conventional chemotherapy with an anticancer agent is easily generated, making it difficult to treat effectively.
  • the 10-year survival rate is very low, less than 10% despite the recent development of cancer therapy. Therefore, it is very important to develop a treatment for such non-small cell lung cancer.
  • Psoraleae Semen ( Psoraleae Semen ) ( Psoralea corylifolia Linne) contains resin, essential oil, bakuchiol, psoralen, angelicin, bavachin, isobavachin, etc.
  • the bark contains psoralidin, corylifolin as main ingredients and improves kidney function It is known as an excellent anti-inflammatory and analgesic medicine.
  • Pagoji stems have yellowish-white hairs and dark brown epochs, and the leaves regenerate.
  • These bones contain essential oils and organic acids, coronary artery dilation and antimicrobial action, etc.
  • the kidneys and reproductive function, and the external treatment of the back wind and the bone is said to have a strong effect.
  • bakuchiol one of the constituents of bone bone, has the action of antibacterial, corn, calcification of bone, and the like.
  • Pgolgoji ( ⁇ , Psoralea fructus ) refers to the mature fruit of Pagoji ( ⁇ ⁇ ⁇ , Psoralea coylifolia L.) belonging to the legume (Leguminosae), the shape of the kidney is a little flat, 3-5 mm long , 2-4 mm wide, about 2 mm thick, the outer surface is black to black brown or grayish brown with a small net-like pattern. The upper part is round and there is one small bump, the fruit mark is dented, and the cut surface is yellowish white with 2 cotyledons and greasy. The taste is spicy, bitter and fragrant.
  • the present inventors completed the present invention by confirming that the Bogolgol extract can effectively kill lung cancer cells while studying the herbal medicine for the bone bone.
  • the present invention provides a composition for the prevention and treatment of lung cancer comprising the active ingredient extracted bone bones with an organic solvent.
  • the organic solvent is preferably ethanol.
  • the present invention provides a cosmetic composition for preventing lung cancer containing Bogolji ethanol extract containing cosmetically acceptable cosmetic supplement additive as an active ingredient.
  • the present invention provides a composition for the prevention and treatment of lung cancer containing Psoraleae Semen ethanol extract as an active ingredient.
  • the composition of the present invention comprises a bone extract as an active ingredient, and may further comprise a pharmaceutically acceptable carrier or diluent.
  • the ethanol extract is preferably extracted for 24 hours at 50 °C, wherein the ethanol extract is more preferably dried and concentrated under 45 °C reduced pressure conditions, the ethanol is Most preferred is 95%.
  • the lung cancer is preferably non-small cell lung cancer, wherein the non-small cell lung cancer is adenocarcinoma (adenocarcinoma), squamous cell carcinoma (squamous cell carcinoma) and large cell cancer ( More preferably caused by a carcinoma selected from the crowd consisting of large cell carcinoma.
  • adenocarcinoma adenocarcinoma
  • squamous cell carcinoma squamous cell carcinoma
  • large cell cancer More preferably caused by a carcinoma selected from the crowd consisting of large cell carcinoma.
  • lung cancer refers to a malignant tumor occurring in the lung, and includes both small cell lung cancer and non-small cell lung cancer such as adenocarcinoma, squamous cell carcinoma, and large cell lung cancer.
  • the "pharmaceutically acceptable carrier” is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.
  • composition for treating lung cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient.
  • the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
  • Formulation for pharmacological Bogolji extract of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical formulations, when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrant And diluents such as surfactants or excipients.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.
  • liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.
  • various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.
  • the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng (Gingseng), Liriopis Tuber, Poly
  • composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • calcium or vitamin D 3 may be added to enhance the efficacy of the treatment.
  • Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as water for injection Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.
  • the formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination.
  • the invention also includes formulations of dosage units.
  • the formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage.
  • Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times.
  • the individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
  • extract refers to an active ingredient isolated from natural products.
  • the extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.
  • the ethanol extract of Bogolji killed A549 non-small cell lung cancer cells at 100 ⁇ g / ml and 97.8%, and EC 50 (half maximal effective concentration) was 29.2 ⁇ g / ml.
  • Bogolji extract of the present invention has excellent killing activity of A549 non-small cell lung cancer cells, and further has lung cancer treatment and prophylactic activity.
  • prevention means any action that inhibits or delays the development of lung cancer by administration of the composition.
  • treatment means any action that improves or advantageously changes the symptoms of lung cancer by administration of the composition.
  • Bogolji extract in the present invention can be used to extract using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol.
  • the extracted solution can be used directly or can be concentrated and / or dried.
  • methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.
  • the extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
  • Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.
  • Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration.
  • the drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
  • the extract can perform an additional fractionation process.
  • the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • the term "pharmaceutically acceptable salts” means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases.
  • suitable acid include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.
  • the pharmaceutical composition for preventing and treating lung cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition.
  • the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like.
  • the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as.
  • the composition may include a substance having a therapeutic activity against lung cancer, used alone or previously used.
  • the term “patient” refers to humans, horses, sheep, pigs, goats, camels, who have disease caused by lung cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention. Means antelope, dog and other animals.
  • a composition comprising the bone extract of the present invention, it is possible to effectively prevent and treat the above-mentioned lung cancer.
  • the composition of the present invention can be administered in parallel with existing lung cancer therapeutics.
  • the term "administration” means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered.
  • the composition may be administered by any device in which the active agent may migrate to the target cell.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses.
  • the method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration.
  • the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day.
  • Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.
  • the present invention provides a cosmetic composition for preventing lung cancer containing Bogolji ethanol extract containing cosmetically acceptable cosmetic supplement additive as an active ingredient.
  • the cosmetic composition of the present invention preferably contains 0.01 to 10% by weight, and more preferably 0.1 to 1% by weight, based on the total weight of the ethanol extract.
  • the cosmetic composition of the present invention is not particularly limited in the formulation, for example, it may have a flexible cosmetic water, nourishing cosmetics, massage cream, nutrition cream, pack, gel or skin adhesive type cosmetic formulation, and also lotion, It may be a transdermal dosage form such as an ointment, gel, cream, patch or spray.
  • the present invention when the Bogolji extract of the present invention was injected into A549 non-small cell lung cancer cells, it was confirmed that A549 non-small cell lung cancer cells were killed (see FIG. 1 ). Therefore, it can be seen that Bogolgol extract has a lung cancer treatment effect.
  • the present invention was completed by preparing a cosmetic composition for preventing lung cancer containing Bogolji extract as an active ingredient (see Preparation Example 2 ).
  • the golgol extract of the present invention inhibits the growth of lung cancer cells and induces apoptosis. Therefore, the composition for treating lung cancer according to the present invention will be very effective in the treatment of lung cancer patients.
  • A549 non-small cell lung cancer cells which are human lung cancer cells, wherein the X axis is the concentration of the bone bone extract, and the Y axis is alive. Survival rate of human lung cancer cells.
  • A549 non-small cell lung cancer cells which are human lung cancer cells, were treated with ethanol extract of Bogolgol for 48 hours and subjected to Alamar Blue analysis.
  • the Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.
  • A549 cells, a lung cancer cell line used in the present invention were distributed from the Korean Cell Line Bank (KCLB) and used for experiments. Specifically, A549 lung cancer cells RPMI 1640 medium (Robwell Park Memorial) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Subculture was performed in a floating culture medium researched and developed by the Institute.
  • KCLB Korean Cell Line Bank
  • Bogolji extract extracted in Example 1 was confirmed the effect of inhibiting the growth of lung cancer cells A549 non-small cell. Specifically, 1.4 X 10 per each well in a 96 well plate 3 Seeds of A549 lung cancer cells incubated for 24 hours and then dissolved in dimethyl sulfoxide (DMSO) When the ethanol extract was treated at concentrations of 0 to 100 ⁇ g / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50 and 100 ⁇ g / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1).
  • golgol has the effect of treating lung cancer. That is, lung cancer cells were killed at 0.2% at 3.125 ⁇ g / ml, 12.4% at 12.5 ⁇ g / ml, 36.7% at 25 ⁇ g / ml, 83.8% at 50 ⁇ g / ml, and 97.8% at 100 ⁇ g / ml.
  • the EC 50 half maximal effective concentration was determined to be 29.2 ⁇ g / ml.
  • Table 1 above describes the relative cell numbers of lung cancer cells after 48 hours according to the concentrations of each of the bones on the basis of the survival rate of the lung cancer cells of the control group not treated with the bones.
  • the Bogolgol extract of the present invention demonstrates excellent A549 non-small cell lung cancer cell killing activity, and further has lung cancer treatment and prophylactic activity.
  • the bone bone used in the present invention was widely used as a medicinal herb, so it was judged that there would be no problem in stability.
  • Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg in suspension of the Bogolji extract of Example 1 of the present invention in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed, and autopsy was performed to observe abdominal and thoracic organ abnormalities.
  • the Bogolgi extract did not show any toxic change up to 5 g / kg in rats and the minimum lethal dose (LD 50 ) was determined to be a safe substance of 5 g / kg or more.
  • the present inventors have confirmed that the bolgolgi extract has excellent lung cancer treatment efficacy through the above example, and prepared a lung cancer treatment agent containing the extract as an active ingredient as follows.
  • the preparation of the following therapeutic agents can be used for the application of not only therapeutic agents but also cosmetic compositions.
  • the present inventors have confirmed that the Bogolgol extract has excellent lung cancer treatment activity through the above-described embodiment to prepare a cosmetic composition containing the same as an active ingredient as follows.
  • the nourishing cream was prepared by a conventional method according to the composition described below.
  • Glycerin 4.0%, Polyvinyl Alcohol 15.0%, Hyaluronic Acid Extract 5.0%, Beta Glucan 7.0%, Allantoin 0.1%, Bogol Extract 0.5%, Nonyl Phenyl Ether 0.4%, Polysorbate 60 1.2%, Ethanol 6.0%, Purified Water Residue
  • Ointments were prepared in a conventional manner according to the compositions described below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une nouvelle utilisation d'un extrait de semence de Psoraleae, et plus particulièrement, une composition pour le traitement du cancer du poumon et une composition pour des produits cosmétiques contenant, comme ingrédient actif, un extrait de semence de Psoraleae ayant d'excellents effets prophylactiques et thérapeutiques sur le cancer du poumon. L'extrait de semence de Psoraleae, selon la présente invention, élimine la prolifération des cellules cancéreuses dans le poumon et induit leur apoptose, et peut ainsi être utilisé efficacement dans la prophylaxie et le traitement du cancer du poumon.
PCT/KR2012/002273 2011-03-28 2012-03-28 Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait de semence de psoraleae Ceased WO2012134165A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110027348A KR20120109782A (ko) 2011-03-28 2011-03-28 보골지 추출물을 포함하는 폐암 치료용 조성물 및 화장료 조성물
KR10-2011-0027348 2011-03-28

Publications (2)

Publication Number Publication Date
WO2012134165A2 true WO2012134165A2 (fr) 2012-10-04
WO2012134165A3 WO2012134165A3 (fr) 2013-03-07

Family

ID=46932117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002273 Ceased WO2012134165A2 (fr) 2011-03-28 2012-03-28 Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait de semence de psoraleae

Country Status (2)

Country Link
KR (1) KR20120109782A (fr)
WO (1) WO2012134165A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010110001A (ko) * 2000-06-05 2001-12-12 최희진 개암풀 추출물을 함유하는 화장료 조성물
US20030035851A1 (en) * 2001-02-08 2003-02-20 Sophie Chen Anti-cancer agents and method of use thereof
TWI264307B (en) * 2004-05-14 2006-10-21 Sinphar Pharmaceutical Co Ltd Pharmaceutical composition containing bakuchiol for treating woman breast cancer
KR101144197B1 (ko) * 2009-03-31 2012-05-11 전남대학교산학협력단 신생혈관형성 억제제 및 이를 이용한 천연산물 항비만제

Also Published As

Publication number Publication date
WO2012134165A3 (fr) 2013-03-07
KR20120109782A (ko) 2012-10-09

Similar Documents

Publication Publication Date Title
WO2012134169A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de semence de gleditsiae
KR20120122407A (ko) 석곡 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2012134252A2 (fr) Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis
KR20130022724A (ko) 호로파 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2012134250A2 (fr) Composition pour le traitement du cancer du rein et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20120122405A (ko) 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
KR20120111765A (ko) 백두구 추출물을 포함하는 폐암 치료용 조성물 및 화장료 조성물
WO2012134168A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait d'herbe de lysimachia foenum-graecum
KR20120092274A (ko) 애엽 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
KR20130025336A (ko) 천초근 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20120092280A (ko) 천초근 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
KR20180043763A (ko) 관중 추출물을 포함하는 폐암 치료용 조성물
WO2014077432A1 (fr) Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques
WO2012134251A2 (fr) Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20120109787A (ko) 소자 추출물을 포함하는 폐암 치료용 조성물 및 화장료 조성물
KR20120122409A (ko) 소자 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens
WO2012134163A2 (fr) Composition pour le traitement du cancer du poumon et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
WO2012134170A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait de racine de rubia
KR20130027064A (ko) 청피 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2012134167A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium
WO2014069695A1 (fr) Composition pour traiter le cancer du pancréas et aliment santé fonctionnel contenant un extrait de boswellia
KR20130023169A (ko) 천초근 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2014069687A1 (fr) Composition pour traiter le cancer rénal et composition cosmétique contenant un extrait de semence de pharbitidis
WO2014069688A1 (fr) Composition pour traiter le cancer rénal et composition cosmétique contenant un extrait de graine de perilla

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12763741

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12763741

Country of ref document: EP

Kind code of ref document: A2